AIM ImmunoTech (AIM) Q4 2024 earnings summary

Executive summary

• Advanced Ampligen clinical programs, including new studies in influenza and post-COVID conditions.

• Strengthened leadership with two new board members bringing extensive investment and operational experience.

• Achieved key milestones in pancreatic cancer, ovarian cancer, melanoma, and breast cancer trials.

• Expanded intellectual property with new patents in endometriosis and post-COVID fatigue.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled approximately $4 million as of December 31, 2024.

• Research and development expenses for 2024 were $6.2 million, down from $10.9 million in 2023.

• General and administrative expenses for 2024 were $13.7 million, down from $21.1 million in 2023.

Outlook and guidance

• Anticipates final patient enrollment in the DURIPANC pancreatic cancer study by Q2 or Q3 2026.

• Advanced ovarian cancer study expected to complete in H1 2025, with data soon after.

• Refractory melanoma and triple-negative breast cancer studies progressing, with key milestones in 2025 and 2026.

• Planning a follow-up study in long COVID and a new influenza vaccine study.